Lessons from phase III clinical trials on anti-VEGF therapy for cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-01

AUTHORS

Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler

ABSTRACT

Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed. More... »

PAGES

24-40

References to SciGraph publications

  • 2004-01-25. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer in NATURE MEDICINE
  • 2002-03. Herceptin acts as an anti-angiogenic cocktail in NATURE
  • 2003-06-01. The biology of VEGF and its receptors in NATURE MEDICINE
  • 2001-09. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy in NATURE MEDICINE
  • 2004-06-01. The anti-angiogenic basis of metronomic chemotherapy in NATURE REVIEWS CANCER
  • 1998-11. A 2-week pretreatment with 13-cis-retinoic acid + interferon-α-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers in STRAHLENTHERAPIE UND ONKOLOGIE
  • 2003-06-01. Molecular regulation of vessel maturation in NATURE MEDICINE
  • 2003-03-04. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells in BRITISH JOURNAL OF CANCER
  • 2005-06. News Analysis in NATURE REVIEWS DRUG DISCOVERY
  • 2004-01-06. Angiogenesis inhibitors in clinical development; where are we now and where are we going? in BRITISH JOURNAL OF CANCER
  • 2004-05-01. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer in NATURE REVIEWS DRUG DISCOVERY
  • 1994-07. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma in ANNALS OF SURGICAL ONCOLOGY
  • 1997-03. Interstitial fluid pressure in intracranial tumours in patients and in rodents in BRITISH JOURNAL OF CANCER
  • 2000-09. Angiogenesis in cancer and other diseases in NATURE
  • 2002-10. Clinical translation of angiogenesis inhibitors in NATURE REVIEWS CANCER
  • 2005-02-14. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma in LABORATORY INVESTIGATION
  • 2002-11-01. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? in NATURE REVIEWS CANCER
  • 2002. The Role of Neuropilin in Vascular and Tumor Biology in NEUROPILIN
  • 2005-06-20. Repopulation of cancer cells during therapy: an important cause of treatment failure in NATURE REVIEWS CANCER
  • 1996-06. A systems approach to cancer therapy in CANCER AND METASTASIS REVIEWS
  • 2003-06-10. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 in BRITISH JOURNAL OF CANCER
  • 2005-12-14. Angiogenesis in life, disease and medicine in NATURE
  • 2005-02-21. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells in ONCOGENE
  • 2005-06-05. Multi-kinase inhibitors create buzz at ASCO in NATURE BIOTECHNOLOGY
  • 2005-05-01. ATM regulates target switching to escalating doses of radiation in the intestines in NATURE MEDICINE
  • Journal

    TITLE

    Nature Reviews Clinical Oncology

    ISSUE

    1

    VOLUME

    3

    Author Affiliations

    Related Patents

  • Uracil Derivatives As Axl And C-Met Kinase Inhibitors
  • Neuropilin Antagonists
  • Compounds For Inhibiting Cell Proliferation In Egfr-Driven Cancers
  • Her-1, Her-3 And Igf-1r Compositions And Uses Thereof
  • Compounds For The Treatment Of Neurodegenerative And Metabolic Disorders
  • Compositions And Methods For The Delivery Of Oxygen
  • Compositions And Methods For The Delivery Of Oxygen
  • Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer
  • Il-8 Level Based Method Of Predicting The Outcome Of Colon Cancer Treatment
  • Imidazo[1,2-B][1,2,4]Triazines As C-Met Inhibitors
  • Substituted Thiazolopyrimidines
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Binding Polypeptides With Diversified And Consensus Vh/Vl Hypervariable Sequences
  • Single Nucleotide Polymorphisms In The Promoter Of Vegfa Gene And Their Use As Predictive Markers For Anti-Vegf Treatments
  • Human Pd1 Peptide Vaccines And Uses Thereof
  • Neuropilin Antagonists
  • Binding Polypeptides With Diversified And Consensus Vh/Vl Hypervariable Sequences
  • Hydrogel Polymeric Compositions And Methods
  • Anti-Invasive Compounds
  • Antibodies That Bind To Jagged 1
  • Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
  • Compounds That Modulate Egfr Activity And Methods For Treating Or Preventing Conditions Therewith
  • Compositions And Methods For The Delivery Of Nitric Oxide
  • Composition Comprising Aflibercept, Folinic Acid, 5-Fluorouracil (5-Fu) And Irinotecan (Folfiri)
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Adhesive Hydrogels For Ophthalmic Drug Delivery
  • Targeted Treatment Of Anerobic Cancer
  • Phosphorus Derivatives As Kinase Inhibitors
  • Compositions And Methods For The Delivery Of Nitric Oxide
  • Methods And Compositions For Targeted Imaging
  • Her-1, Her-3 And Igf-1r Compositions And Uses Thereof
  • Compositions And Methods For The Delivery Of Oxygen
  • Anti-Neuropilin Antibodies And Methods Of Use
  • Hydrogel Polymeric Compositions And Methods
  • Neuropilin Antagonists
  • Hydrogel Polymeric Compositions And Methods
  • Methods For Inhibiting Cell Proliferation In Alk-Driven Cancers
  • Medical Organogel Processes And Compositions
  • Imidazotriaines And Imidazopyrimidines As Kinase Inhibitors
  • Tumor Therapy With An Anti-Vegf Antibody
  • Drug Delivery Through Hydrogel Plugs
  • Imidazotriaines And Imidazopyrimidines As Kinase Inhibitors
  • Hydrogel Polymeric Compositions And Methods
  • Hydrogel Polymeric Compositions And Methods
  • Drug Delivery From Hydrogels
  • Targeted Treatment Of Anerobic Cancer
  • Neuropilin Antagonists
  • Thienopyrimidines
  • Drug Delivery Through Hydrogel Plugs
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/ncponc0403

    DOI

    http://dx.doi.org/10.1038/ncponc0403

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1035025701

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16407877


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angiogenesis Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bevacizumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase III as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neovascularization, Pathologic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vascular Endothelial Growth Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jain", 
            "givenName": "Rakesh K", 
            "id": "sg:person.01340416322.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340416322.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Duda", 
            "givenName": "Dan G", 
            "id": "sg:person.01237474607.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237474607.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Clark", 
            "givenName": "Jeffrey W", 
            "id": "sg:person.011711024742.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711024742.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Loeffler", 
            "givenName": "Jay S", 
            "id": "sg:person.0670037777.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670037777.04"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/bjc.1997.148", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020183468", 
              "https://doi.org/10.1038/bjc.1997.148"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4615-0119-0_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004215273", 
              "https://doi.org/10.1007/978-1-4615-0119-0_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208246", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042851524", 
              "https://doi.org/10.1038/sj.onc.1208246"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1768", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006224824", 
              "https://doi.org/10.1038/nrd1768"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044464024", 
              "https://doi.org/10.1038/sj.bjc.6601005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03187139", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025273729", 
              "https://doi.org/10.1007/bf03187139"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1650", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026450668", 
              "https://doi.org/10.1038/nrc1650"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0603-685", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023460594", 
              "https://doi.org/10.1038/nm0603-685"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1237", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020754853", 
              "https://doi.org/10.1038/nm1237"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35025220", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043028620", 
              "https://doi.org/10.1038/35025220"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/labinvest.3700252", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014059182", 
              "https://doi.org/10.1038/labinvest.3700252"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc925", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015283659", 
              "https://doi.org/10.1038/nrc925"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601401", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007664387", 
              "https://doi.org/10.1038/sj.bjc.6601401"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6600811", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008965461", 
              "https://doi.org/10.1038/sj.bjc.6600811"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/416279b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035406433", 
              "https://doi.org/10.1038/416279b"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature04478", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011948458", 
              "https://doi.org/10.1038/nature04478"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1369", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019159796", 
              "https://doi.org/10.1038/nrc1369"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03038294", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028287402", 
              "https://doi.org/10.1007/bf03038294"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc905", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017804909", 
              "https://doi.org/10.1038/nrc905"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0603-669", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031340920", 
              "https://doi.org/10.1038/nm0603-669"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0901-987", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053699875", 
              "https://doi.org/10.1038/nm0901-987"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1381", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006489607", 
              "https://doi.org/10.1038/nrd1381"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm988", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003700365", 
              "https://doi.org/10.1038/nm988"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00437479", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007205974", 
              "https://doi.org/10.1007/bf00437479"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0605-639", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033074581", 
              "https://doi.org/10.1038/nbt0605-639"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2006-01", 
        "datePublishedReg": "2006-01-01", 
        "description": "Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/ncponc0403", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2435727", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1034153", 
            "issn": [
              "1759-4774", 
              "1759-4782"
            ], 
            "name": "Nature Reviews Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "3"
          }
        ], 
        "keywords": [
          "cancer patients", 
          "refractory metastatic breast cancer", 
          "phase III clinical trials", 
          "progression-free survival", 
          "metastatic breast cancer", 
          "anti-VEGF therapy", 
          "breast cancer patients", 
          "lung cancer patients", 
          "standard chemotherapy", 
          "overall survival", 
          "patient selection", 
          "clinical trials", 
          "breast cancer", 
          "oxygen delivery", 
          "tumor vasculature", 
          "patients", 
          "survival", 
          "cancer", 
          "improved drugs", 
          "chemotherapy", 
          "colorectal", 
          "therapy", 
          "trials", 
          "biomarkers", 
          "vasculature", 
          "drugs", 
          "delivery", 
          "normalization", 
          "mechanism", 
          "need", 
          "combination", 
          "reasons", 
          "results", 
          "protocol design", 
          "technique", 
          "selection", 
          "lessons", 
          "design"
        ], 
        "name": "Lessons from phase III clinical trials on anti-VEGF therapy for cancer", 
        "pagination": "24-40", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1035025701"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/ncponc0403"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16407877"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/ncponc0403", 
          "https://app.dimensions.ai/details/publication/pub.1035025701"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:25", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_421.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/ncponc0403"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'


     

    This table displays all metadata directly associated to this object as RDF triples.

    276 TRIPLES      21 PREDICATES      101 URIs      68 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/ncponc0403 schema:about N251110cfa04d43dea5001c8c863e5400
    2 N3e6515a0be6c42e2970b135d6aff720d
    3 N61133049ab374fd2b636f9808f50124a
    4 N66f335af61da4a918ca54881702bc19a
    5 N684ee4412c754195bc425cb7c48e139b
    6 N83e1a10f4cb24c3db62986312016a448
    7 N877a2b84a4e14adf903a417487a045b3
    8 N936beb9e0d3e43b2b7aa095355a438e0
    9 Nce2dba1016874dcd8b1af55662a99a88
    10 Nd13a88d2e8d84f05a73914d21376c2f7
    11 Nd696cc4d940847ef8270ce460f883091
    12 Ndf16b2e69b8e4bb7bf68f0e554122ad9
    13 anzsrc-for:11
    14 anzsrc-for:1112
    15 schema:author Nd9af3b325a94402aad9c627a20079941
    16 schema:citation sg:pub.10.1007/978-1-4615-0119-0_3
    17 sg:pub.10.1007/bf00437479
    18 sg:pub.10.1007/bf03038294
    19 sg:pub.10.1007/bf03187139
    20 sg:pub.10.1038/35025220
    21 sg:pub.10.1038/416279b
    22 sg:pub.10.1038/bjc.1997.148
    23 sg:pub.10.1038/labinvest.3700252
    24 sg:pub.10.1038/nature04478
    25 sg:pub.10.1038/nbt0605-639
    26 sg:pub.10.1038/nm0603-669
    27 sg:pub.10.1038/nm0603-685
    28 sg:pub.10.1038/nm0901-987
    29 sg:pub.10.1038/nm1237
    30 sg:pub.10.1038/nm988
    31 sg:pub.10.1038/nrc1369
    32 sg:pub.10.1038/nrc1650
    33 sg:pub.10.1038/nrc905
    34 sg:pub.10.1038/nrc925
    35 sg:pub.10.1038/nrd1381
    36 sg:pub.10.1038/nrd1768
    37 sg:pub.10.1038/sj.bjc.6600811
    38 sg:pub.10.1038/sj.bjc.6601005
    39 sg:pub.10.1038/sj.bjc.6601401
    40 sg:pub.10.1038/sj.onc.1208246
    41 schema:datePublished 2006-01
    42 schema:datePublishedReg 2006-01-01
    43 schema:description Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N7137dcb967b54c17acdb8be8941a01a6
    47 N9ac07becd8284c87a356197725d49f6c
    48 sg:journal.1034153
    49 schema:keywords anti-VEGF therapy
    50 biomarkers
    51 breast cancer
    52 breast cancer patients
    53 cancer
    54 cancer patients
    55 chemotherapy
    56 clinical trials
    57 colorectal
    58 combination
    59 delivery
    60 design
    61 drugs
    62 improved drugs
    63 lessons
    64 lung cancer patients
    65 mechanism
    66 metastatic breast cancer
    67 need
    68 normalization
    69 overall survival
    70 oxygen delivery
    71 patient selection
    72 patients
    73 phase III clinical trials
    74 progression-free survival
    75 protocol design
    76 reasons
    77 refractory metastatic breast cancer
    78 results
    79 selection
    80 standard chemotherapy
    81 survival
    82 technique
    83 therapy
    84 trials
    85 tumor vasculature
    86 vasculature
    87 schema:name Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    88 schema:pagination 24-40
    89 schema:productId N4d8a08d979364fe8a3667cefcb4edcd4
    90 N66e874ad0d2848f2afb4bab2eda9e77c
    91 N7d1ad4e611be45dc87a938d08d3ec050
    92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035025701
    93 https://doi.org/10.1038/ncponc0403
    94 schema:sdDatePublished 2022-12-01T06:25
    95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    96 schema:sdPublisher N7919949112a4449ea72cbca33786660b
    97 schema:url https://doi.org/10.1038/ncponc0403
    98 sgo:license sg:explorer/license/
    99 sgo:sdDataset articles
    100 rdf:type schema:ScholarlyArticle
    101 N0496baf2112843a38da96d4e874eca0d rdf:first sg:person.01237474607.21
    102 rdf:rest Nc3146e4a8162462a96ff6e3000fdaf60
    103 N24e38ee6d7244f56b6b19e28762f6eab rdf:first sg:person.0670037777.04
    104 rdf:rest rdf:nil
    105 N251110cfa04d43dea5001c8c863e5400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Neovascularization, Pathologic
    107 rdf:type schema:DefinedTerm
    108 N3e6515a0be6c42e2970b135d6aff720d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Angiogenesis Inhibitors
    110 rdf:type schema:DefinedTerm
    111 N4d8a08d979364fe8a3667cefcb4edcd4 schema:name dimensions_id
    112 schema:value pub.1035025701
    113 rdf:type schema:PropertyValue
    114 N61133049ab374fd2b636f9808f50124a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Protein-Tyrosine Kinases
    116 rdf:type schema:DefinedTerm
    117 N66e874ad0d2848f2afb4bab2eda9e77c schema:name pubmed_id
    118 schema:value 16407877
    119 rdf:type schema:PropertyValue
    120 N66f335af61da4a918ca54881702bc19a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Antibodies, Monoclonal, Humanized
    122 rdf:type schema:DefinedTerm
    123 N684ee4412c754195bc425cb7c48e139b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Vascular Endothelial Growth Factors
    125 rdf:type schema:DefinedTerm
    126 N7137dcb967b54c17acdb8be8941a01a6 schema:volumeNumber 3
    127 rdf:type schema:PublicationVolume
    128 N7919949112a4449ea72cbca33786660b schema:name Springer Nature - SN SciGraph project
    129 rdf:type schema:Organization
    130 N7d1ad4e611be45dc87a938d08d3ec050 schema:name doi
    131 schema:value 10.1038/ncponc0403
    132 rdf:type schema:PropertyValue
    133 N83e1a10f4cb24c3db62986312016a448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Humans
    135 rdf:type schema:DefinedTerm
    136 N877a2b84a4e14adf903a417487a045b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Antineoplastic Agents
    138 rdf:type schema:DefinedTerm
    139 N936beb9e0d3e43b2b7aa095355a438e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Clinical Trials, Phase III as Topic
    141 rdf:type schema:DefinedTerm
    142 N9ac07becd8284c87a356197725d49f6c schema:issueNumber 1
    143 rdf:type schema:PublicationIssue
    144 Nc3146e4a8162462a96ff6e3000fdaf60 rdf:first sg:person.011711024742.39
    145 rdf:rest N24e38ee6d7244f56b6b19e28762f6eab
    146 Nce2dba1016874dcd8b1af55662a99a88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Neoplasms
    148 rdf:type schema:DefinedTerm
    149 Nd13a88d2e8d84f05a73914d21376c2f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Antibodies, Monoclonal
    151 rdf:type schema:DefinedTerm
    152 Nd696cc4d940847ef8270ce460f883091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Bevacizumab
    154 rdf:type schema:DefinedTerm
    155 Nd9af3b325a94402aad9c627a20079941 rdf:first sg:person.01340416322.96
    156 rdf:rest N0496baf2112843a38da96d4e874eca0d
    157 Ndf16b2e69b8e4bb7bf68f0e554122ad9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Biomarkers, Tumor
    159 rdf:type schema:DefinedTerm
    160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    161 schema:name Medical and Health Sciences
    162 rdf:type schema:DefinedTerm
    163 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    164 schema:name Oncology and Carcinogenesis
    165 rdf:type schema:DefinedTerm
    166 sg:grant.2435727 http://pending.schema.org/fundedItem sg:pub.10.1038/ncponc0403
    167 rdf:type schema:MonetaryGrant
    168 sg:journal.1034153 schema:issn 1759-4774
    169 1759-4782
    170 schema:name Nature Reviews Clinical Oncology
    171 schema:publisher Springer Nature
    172 rdf:type schema:Periodical
    173 sg:person.011711024742.39 schema:affiliation grid-institutes:grid.32224.35
    174 schema:familyName Clark
    175 schema:givenName Jeffrey W
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711024742.39
    177 rdf:type schema:Person
    178 sg:person.01237474607.21 schema:affiliation grid-institutes:grid.32224.35
    179 schema:familyName Duda
    180 schema:givenName Dan G
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237474607.21
    182 rdf:type schema:Person
    183 sg:person.01340416322.96 schema:affiliation grid-institutes:grid.32224.35
    184 schema:familyName Jain
    185 schema:givenName Rakesh K
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340416322.96
    187 rdf:type schema:Person
    188 sg:person.0670037777.04 schema:affiliation grid-institutes:grid.32224.35
    189 schema:familyName Loeffler
    190 schema:givenName Jay S
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670037777.04
    192 rdf:type schema:Person
    193 sg:pub.10.1007/978-1-4615-0119-0_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004215273
    194 https://doi.org/10.1007/978-1-4615-0119-0_3
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/bf00437479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007205974
    197 https://doi.org/10.1007/bf00437479
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1007/bf03038294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028287402
    200 https://doi.org/10.1007/bf03038294
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1007/bf03187139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025273729
    203 https://doi.org/10.1007/bf03187139
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1038/35025220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043028620
    206 https://doi.org/10.1038/35025220
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1038/416279b schema:sameAs https://app.dimensions.ai/details/publication/pub.1035406433
    209 https://doi.org/10.1038/416279b
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1038/bjc.1997.148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020183468
    212 https://doi.org/10.1038/bjc.1997.148
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1038/labinvest.3700252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014059182
    215 https://doi.org/10.1038/labinvest.3700252
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1038/nature04478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011948458
    218 https://doi.org/10.1038/nature04478
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1038/nbt0605-639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033074581
    221 https://doi.org/10.1038/nbt0605-639
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1038/nm0603-669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031340920
    224 https://doi.org/10.1038/nm0603-669
    225 rdf:type schema:CreativeWork
    226 sg:pub.10.1038/nm0603-685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023460594
    227 https://doi.org/10.1038/nm0603-685
    228 rdf:type schema:CreativeWork
    229 sg:pub.10.1038/nm0901-987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053699875
    230 https://doi.org/10.1038/nm0901-987
    231 rdf:type schema:CreativeWork
    232 sg:pub.10.1038/nm1237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020754853
    233 https://doi.org/10.1038/nm1237
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1038/nm988 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003700365
    236 https://doi.org/10.1038/nm988
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1038/nrc1369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019159796
    239 https://doi.org/10.1038/nrc1369
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1038/nrc1650 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026450668
    242 https://doi.org/10.1038/nrc1650
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1038/nrc905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017804909
    245 https://doi.org/10.1038/nrc905
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/nrc925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015283659
    248 https://doi.org/10.1038/nrc925
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1038/nrd1381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006489607
    251 https://doi.org/10.1038/nrd1381
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1038/nrd1768 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006224824
    254 https://doi.org/10.1038/nrd1768
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1038/sj.bjc.6600811 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008965461
    257 https://doi.org/10.1038/sj.bjc.6600811
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/sj.bjc.6601005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044464024
    260 https://doi.org/10.1038/sj.bjc.6601005
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/sj.bjc.6601401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007664387
    263 https://doi.org/10.1038/sj.bjc.6601401
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1038/sj.onc.1208246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042851524
    266 https://doi.org/10.1038/sj.onc.1208246
    267 rdf:type schema:CreativeWork
    268 grid-institutes:grid.32224.35 schema:alternateName MGH, Boston, MA, USA
    269 schema:name Dana-Farber/Partners Cancer Care
    270 Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)
    271 HMS
    272 MGH
    273 MGH Cancer Center
    274 MGH, Boston, MA, USA
    275 Tumor Biology at Harvard Medical School (HMS)
    276 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...